MedTrace Logo

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

NCT05421065 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-17

No results posted yet for this study

Summary

This pilot study will collect preliminary data that measures the effects of psilocybin-assisted psychotherapy vs ketamine-assisted psychotherapy on patients struggling with alcohol use.

Conditions

Interventions

DRUG

Psilocybin

1 oral dose

DRUG

Ketamine

1 oral dose

Sponsors & Collaborators

  • Peggy C Nopoulos

    lead OTHER

Principal Investigators

  • Peggy C Nopoulos, MD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2025-08-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05421065 on ClinicalTrials.gov